Novo NordiskSee all their emails

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

A real announcement email from Novo Nordisk. Captured September 29, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596 email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk announces an exclusive license agreement with Hengrui Pharma for HRS-1596, an oral GLP-1/GIP dual receptor agonist.

Logo at top left, followed by bullet points highlighting deal details, then a standard corporate press release layout with multiple paragraphs, contact information tables, and legal footer.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.